Dr. Reddys Laboratories Ltd 2018 AR2
The report outlines the financial and operational performance of the company for the fiscal year 2017-2018. Despite facing pricing pressures and regulatory challenges in the US market, the company achieved consolidated revenues of ₹142 billion, representing a marginal increase of one percent compared to the previous year. Key highlights include the launch of 139 new products globally, including critical launches in the US such as Liposomal Doxorubicin and Sevelamer Carbonate. The company also advanced its sustainability initiatives, achieving a zero solid waste to landfill status at its active pharmaceutical ingredient facilities and increasing its share of renewable energy.
Company: Dr. Reddys Laboratories Ltd
Sector: Health Care
Country: India
Year: 2018
Type: AR2
Pages: 260
Back to company
Dr. Reddys Laboratories Ltd
Annual Report
The report outlines the financial and operational performance of the company for the fiscal year 2017-2018. Despite facing pricing pressures and regulatory challenges in the US market, the company achieved consolidated revenues of ₹142 billion, representing a marginal increase of one percent compared to the previous year. Key highlights include the launch of 139 new products globally, including critical launches in the US such as Liposomal Doxorubicin and Sevelamer Carbonate. The company also advanced its sustainability initiatives, achieving a zero solid waste to landfill status at its active pharmaceutical ingredient facilities and increasing its share of renewable energy.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees